Immunomodulating composition containing gasseri

The combination of FK506 and microbiome strains addresses the limitations of current immunosuppressants by regulating immune responses, effectively suppressing transplant rejection and graft-versus-host disease through reduced Th1 and Th17 activity and increased Treg activity, enhancing therapeutic efficacy and safety.

KR103046606B1Active Publication Date: 2026-11-11THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020240008205
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-01-19
Filing Date
2024-01-18
Publication Date
2026-11-11
Estimated Expiration
2044-01-18

AI Technical Summary

Technical Problem

Current immunosuppressants used for transplantation have significant side effects and are difficult to sustain long-term therapeutic effects, and there is a need for safer and more effective immunomodulatory therapies to manage transplant rejection and graft-versus-host disease.

Method used

A pharmaceutical composition comprising FK506 and specific microbiome strains, such as Lactobacillus rhamnosus and Lactobacillus paracasei, is used to regulate immune responses, reducing Th1 and Th17 activity and increasing Treg activity, thereby suppressing transplant rejection and graft-versus-host disease.

Benefits of technology

The combination of FK506 and microbiome strains effectively suppresses allogeneic reactions, reduces disease activity, increases survival rates, and protects against tissue damage by modulating immune cell activity and cytokine expression, providing a safer and more effective immunosuppressive treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024007075010-PAT00011_ABST
    Figure 112024007075010-PAT00011_ABST
Patent Text Reader

Abstract

The present invention relates to an immunomodulatory therapeutic composition for transplant diseases through the combined administration of a microbiome and an immunosuppressant. It was confirmed that the combined administration of FK506 and the microbiome of the present invention inhibits allogeneic reactions and regulates the activity of T cells and B cells in an allogeneic transplant cell model. Furthermore, it was confirmed that in an animal model of acute graft-versus-host disease, it reduces disease activity, increases survival rate, and protects against tissue damage. Additionally, it was confirmed that it can improve transplant rejection by reducing the activity of Th1 and Th17 cells and increasing the activity of Tregs. Moreover, it was confirmed that the combined administration of FK506 and the microbiome inhibits the proliferation of allogeneic T cells, suppresses the expression of IL-17, and increases the expression of IL-10, an immunomodulatory factor that is reduced by treatment with immunosuppressants. Furthermore, it was confirmed that in stimulated patient-derived PBMCs, it reduces IL-17, increases the expression of IL-10 and IFN-γ, and increases immunomodulatory cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to an immunomodulatory inducing composition comprising gasseri. Background Technology

[0002] The immune system must be able to distinguish between self and non-self. If it fails to make this distinction, the immune system destroys the body's cells and tissues, resulting in autoimmune diseases. Regulatory T cells actively suppress the activation of the immune system to prevent pathological self-reactivity and, consequently, prevent autoimmune diseases. Regulatory T cells (Tregs) are a class of CD4+CD25+ T cells that suppress the activity of other immune cells. The immune system is well-equipped to rapidly identify and destroy alien species, pathogens, or inflammatory tissues. This has been a major barrier to gene therapy as well as tissue, organ, and cell transplantation. The primary issues have generally been chronic immunosuppression, encapsulation, and immune isolation. Unwanted side effects of chronic immunosuppression include increased susceptibility to opportunistic infections and tumor formation.

[0003] The mechanism by which T cell responses to foreign (allogeneic or xenogeneic) proteins, cells, or organs function is quite well understood. At sites of inflammation or injury (induced by transplantation), T cells constantly monitor for the presence of foreign tissues (allogeneic or xenogeneic) or pathogens. Once these warning signals are recognized, APCs digest the allogeneic or xenogeneic pathogens and present them to the host immune system as antigens.

[0004] Transplantation refers to the process of taking cells, tissues, or organs—that is, a graft—from one individual and transferring them to another. The individual providing the graft is called the donor, and the individual receiving it is called the recipient or host. In the case of transplanted organs, rejection occurs due to an immunological reaction to tissue compatibility antigens (transplant antigens) located on the cell surface of the graft. Long-term engraftment in non-immunosuppressed recipients is possible only when tissue compatibility is a perfect or partial match; the genetic relationship between the donor and recipient is a major factor determining the duration of graft engraftment. Generally, rejection rarely occurs in autografts and isografts, but it occurs in almost all xenografts. When transplanting tissues or organs, genetic differences between the donor and the recipient are easily detected by the host immune system, triggering a host-versus-graft response and / or a graft-versus-host response. This fact has been demonstrated by the rejection reactions observed during tissue and organ transplants (Nash et al., Blood, 80, 1838-1845, 1992). Additionally, there have been reports that rejection of allotransplanted tissues occurs due to T cells activated by an immune response to MHC present on the surface of transplanted cells.

[0005] Immunosuppressants that non-specifically suppress T cells to suppress transplant rejection reactions or diseases generally have the disadvantage of being difficult to sustain long-term therapeutic effects because they are accompanied by side effects such as cytotoxicity, infection due to immunosuppression, diabetes, tremors, headaches, diarrhea, hypertension, nausea, and renal dysfunction. Accordingly, methods to combine or replace immunosuppressants with different mechanisms of action have been attempted, particularly in the field of organ transplantation, to reduce serious side effects and enhance the efficacy of immunosuppressive therapy; however, optimized combinations of immunosuppressant administration or therapeutic methods are still lacking. Therefore, there is an urgent need to develop new immunosuppressive or immunomodulatory therapies that can reduce the side effects of existing immunosuppressants and improve therapeutic efficacy, as well as to discover new immunosuppressant candidate substances that are safer and have fewer side effects.

[0006] Meanwhile, currently used immunosuppressants are classified according to their mechanism of action into corticosteroids, antimetabolites, calcineurin inhibitors, mammalian target of rapamycin inhibitors, and antibodies; these exert immunosuppressive effects by blocking the proliferation or activation of T cells in the immune system at different stages. T cells, the primary targets of immunosuppressants, are generated in the thymus and differentiate into Type 1 helper cells (Th1), which are primarily involved in cell-mediated immunity, or Type 2 helper cells (Th2), which are involved in humoral immunity. It is known that these two T cell populations keep each other in check to prevent overactivation, and if this balance is disrupted, adverse reactions such as autoimmunity or hypersensitivity occur.

[0007] In addition, new types of T cells capable of regulating immune responses, such as immunomodulatory T cells (Treg) and Th17, have been identified. Tregs can regulate Th1 cell activity, suppress the function of abnormally activated immune cells, and control inflammatory responses. Conversely, Th17 cells secrete IL-17 and maximize inflammatory signaling, thereby accelerating disease progression. Recently, these Tregs and Th17 have emerged as significant new targets for therapies for immune diseases, leading to research on various immunomodulatory therapies (Wood, KJ et al., Nat. Rev. Immunol. 12(6):417-430, 2012; Miossec, P. et al., Nat. Rev. Drug Discov. 11(10):763-776, 2012; Noack, M. et al., Autoimmun. Rev. 13(6):668-677, 2014).

[0008] Conventional immunosuppressants that non-specifically inhibit T cells generally have the disadvantage of being difficult to sustain long-term therapeutic effects because they are accompanied by side effects such as cytotoxicity, infection due to immunosuppression, diabetes, tremor, headache, diarrhea, hypertension, nausea, and renal dysfunction. Therefore, to reduce serious side effects and enhance the efficacy of immunosuppressive treatment, methods of combining or replacing immunosuppressants with different mechanisms of action have been attempted, particularly in the field of organ transplantation; however, treatment methods using optimized single compounds are still lacking.

[0009] Meanwhile, the term "microbiome" refers to the microorganisms inhabiting the human body, specifically intestinal microbes. The number of microbiome members is more than double that of pure human cells, and the number of genes is over 100 times greater. Consequently, it is impossible to discuss human genes without considering microorganisms, which is why they are sometimes referred to as the "Second Genome." The microbiome is a field that can be widely utilized in new drug development and research into treatments for incurable diseases, as it allows for the analysis of the principles behind the generation of beneficial and harmful bacteria and their correlations with diseases. Furthermore, the microbiome is used in the development of food, cosmetics, and therapeutic agents.

[0010] With the advancement of Next Generation Sequencing (NGS) technology, the importance of gut microorganisms in human physiology and immune regulation is being highlighted, leading to the emergence of probiotics, which can directly regulate the structure of the human gut microbiome. Recent studies have revealed that probiotics are deeply connected to the human microbiome, drawing attention to their function as regulators that alter the intestinal environment. The consumption of probiotics is known to promote digestion through microbiome regulation, as well as inhibit inflammatory bowel disease, infectious diseases, and harmful bacteria. In particular, it has been found to enhance the host's immune system, demonstrating efficacy against various immune-related diseases, including atopic dermatitis and rheumatoid arthritis, as well as cancer.

[0011] In addition, as the field of probiotics has grown significantly, much attention is being focused on prebiotics, synbiotics, and postbiotics. Prebiotics are defined as "substances selectively utilized by beneficial bacteria that contribute to health among the host's microorganisms," with dietary fiber and oligosaccharides serving as food for lactic acid bacteria being representative examples. Synbiotics refer to a form containing both probiotics and prebiotics. Meanwhile, postbiotics, which have recently been attracting attention, are materials containing useful metabolites produced by probiotics and components of microorganisms; they are clearly defined as "non-living forms of microorganisms beneficial to the host's health or formulations containing components of such microorganisms," and postbiotics are receiving attention as new alternative materials capable of overcoming the limitations of safety, function, and stability of existing probiotic materials. The problem to be solved

[0012] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of transplantation rejection or transplantation rejection disease comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain as an active ingredient.

[0013] [Chemical Formula 1]

[0014]

[0015] Another object of the present invention is to provide a pharmaceutical composition for post-transplant immunosuppression comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain as active ingredients. means of solving the problem

[0016] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of transplantation rejection or transplantation rejection disease comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain as an active ingredient.

[0017] [Chemical Formula 1]

[0018]

[0019] In addition, the present invention provides a pharmaceutical composition for post-transplant immunosuppression comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain as active ingredients. Effects of the invention

[0020] It was confirmed that the combined administration of FK506 and the microbiome of the present invention suppresses allogeneic reactions and regulates the activity of T cells and B cells in an allogeneic transplant cell model. Furthermore, it was confirmed that in an animal model of acute graft-versus-host disease, it reduces disease activity, increases survival rate, and protects against tissue damage. Additionally, it was confirmed that it can improve transplant rejection by reducing the activity of Th1 and Th17 cells and increasing the activity of Tregs. Moreover, it was confirmed that the combined administration of FK506 and the microbiome suppresses the proliferation of allogeneic T cells, inhibits the expression of IL-17, and increases the expression of IL-10, an immunomodulatory factor reduced by treatment with immunosuppressants. Furthermore, it was confirmed that in stimulated patient-derived PBMCs, it reduces IL-17, increases the expression of IL-10 and IFN-γ, and increases immunomodulatory cells, thereby confirming that it can be usefully utilized as an immunomodulator for transplant rejection. Brief explanation of the drawing

[0021] Figure 1 is a figure confirming the effect of inhibiting homologous reactions by treating a homologous cell model with the FK506 and microbiome strains of the present invention. Figure 2 is a figure showing the quantification of Th1 and Th17 activities by flow cytometry analysis after treating the FK506 and microbiome strains of the present invention under T cell activation conditions (A: confirmation of Th1 activity, B: confirmation of Th17 activity). Figure 3 shows the analysis of cytokine expression in a culture medium by ELISA after treating the FK506 and microbiome strains of the present invention under T cell activation conditions (A: confirmation of INF-γ expression, B: confirmation of IL-17 expression). Figure 4 shows the regulation of T cell and B cell activity by flow cytometry after administering the FK506 and microbiome strains of the present invention to allogeneic transplant rejection mice (A: Confirmation of T cell regulation, B: Confirmation of B cell regulation). Figure 5 illustrates the experimental process for evaluating the effects of the FK506 and microbiome strains of the present invention in mice with acute graft-versus-host disease. Figure 6 shows the results of confirming the inhibitory effect on graft-versus-host disease activity by administering the FK506 and Lactobacillus paracasei strains of the present invention to mice with acute graft-versus-host disease (A: confirmation of disease activity, B: confirmation of body weight change, C: confirmation of survival rate). Figure 7 shows the results of confirming the inhibitory effect on graft-versus-host disease activity by administering the FK506 and Lactobacillus rhamnosus strains of the present invention to mice with acute graft-versus-host disease (A: confirmation of disease activity, B: confirmation of body weight change, C: confirmation of survival rate). Figure 8 shows the effects of the FK506 and microbiome strains of the present invention administered to mice with acute graft-versus-host disease, confirming the inhibition of liver and intestinal tissue damage by H&E staining (A: confirmation of staining results, B: quantification of staining results). Figure 9 shows the quantification of the T cell activity regulating effect by flow cytometry after administering the FK506 and microbiome strains of the present invention to mice with acute graft-versus-host disease (A: Th1 activity quantification, B: Th17 activity quantification, C: Treg activity quantification, D: CD8-INFγ cell activity quantification). Figure 10 is a figure confirming the proliferation of allogeneic T cells as CCK8 following combined treatment of FK506 and microbiome strains of the present invention. FIG. 11 is a figure showing the expression of inflammation-related factors under homologous reaction conditions following combined treatment with the FK506 and microbiome strain of the present invention, analyzed by ELISA (A: IL-17 confirmed, B: IL-10 confirmed). Figure 12 shows the expression of immune factors in hPBMCs following combined treatment with FK506 and microbiome under T cell stimulation conditions, confirmed by ELISA (A: IL-17 confirmed, B: IL-10 confirmed). Figure 13 is a figure showing the expression of IFN-γ in hPBMCs under T cell stimulation conditions following combined treatment with FK506 and microbiome by ELISA. Figure 14 shows the expression of Treg cells in hPBMCs under T cell stimulation conditions following combined treatment with FK506 and a microbiome, confirmed by flow cytometry (A: flow cytometry results, B: quantification of Treg expression). Figure 15 shows the expression of Breg in hPBMCs under LPS stimulation conditions following combined treatment with FK506 and microbiome by flow cytometry (A: flow cytometry results, B: quantification of Breg expression). Figure 16 shows the expression of B10 in hPBMCs under LPS stimulation conditions following combined treatment with FK506 and microbiome by flow cytometry (A: flow cytometry results, B: quantification of B10 expression). Figure 17 shows the expression of CD19 and IL-10 positive cells in hPBMCs treated with FK506 and microbiome under LPS stimulation conditions, confirmed by flow cytometry (A: flow cytometry results, B: quantification of CD19 and IL-10 positive cell expression). Specific details for implementing the invention

[0022] Embodiments of the present invention will be described in detail below with reference to the attached drawings. In the following description, detailed descriptions of technologies well known to those skilled in the art may be omitted. Furthermore, in describing the present invention, detailed descriptions of related known functions or configurations may be omitted if it is determined that such descriptions would unnecessarily obscure the essence of the present invention. Additionally, the terminology used in this specification is used to appropriately express preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs.

[0023] Therefore, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0024] The present invention provides a pharmaceutical composition for the prevention or treatment of transplantation rejection or transplantation rejection disease comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain as an active ingredient.

[0025] [Chemical Formula 1]

[0026]

[0027] The term "prevention" as used in this invention refers to any act of suppressing the symptoms of a specific disease or delaying its progression through the administration of the composition of this invention.

[0028] The term "treatment" as used in this invention refers to any act of improving or beneficially altering the symptoms of a specific disease through the administration of the composition of this invention.

[0029] The compound of Formula 1 of the present invention is also named FK506 or Tacrolimus, and Streptomyces taukuaensis It is an immunosuppressant produced by

[0030] In addition, the compound represented by Formula 1 according to the present invention can be used in the form of a salt, preferably a pharmaceutically acceptable salt.

[0031] The above term “pharmaceuticalally acceptable salt” means that, within the scope of sound medical judgment, these salts are used in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reactions, and similarities, and are proportional to a reasonable advantage / disadvantage ratio. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of amino groups formed from inorganic acids such as hydrochloric acid, hydrobromide, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or formed using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts are adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, maleate, malieate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, Includes pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valeraate salts, and similar substances.

[0032] Salts derived from suitable bases are alkali metals, alkaline earth metals, ammonium, and N + (C 1-4 It includes alkyl)tetraphosphates. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and similar ones. In addition, pharmaceutically acceptable salts include, when appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxylates, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.

[0033] The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to the active ingredient. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete or incomplete adjuvant may be further included to increase the effect.

[0034] The pharmaceutical composition according to the present invention may be prepared in a form in which an active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0035] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external formulations, suppositories, or sterile injectable solutions according to conventional methods, preferably as an injectable solution (injection), but is not limited thereto.

[0036] The pharmaceutical composition of the present invention may be prepared using diluents or excipients such as fillers, fillers, binders, wetting agents, disintegrants, and surfactants that are commonly used when formulating. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and such solid dosage forms may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. with the active ingredient. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may include various excipients, for example, wetting agents, sweeteners, flavoring agents, and preservatives, in addition to water and liquid paraffin, which are commonly used diluents. Preparations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Water-insoluble solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Bases for suppositories may include Witepsol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc.

[0037] The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration may be anticipated, for example, by oral, intravenous, intramuscular, subcutaneous, intraperitoneal, or intra-articular injection.

[0038] The dosage of the pharmaceutical composition according to the present invention is selected by taking into consideration the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the subject, and preferably, it is included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg / ml. If the concentration is less than 0.01 μg / ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg / ml, it may exhibit toxicity to the human body.

[0039] According to one embodiment of the present invention, the transplant rejection reaction may be a transplant rejection reaction selected from the group consisting of cells, blood, tissues, and organs, and the transplant rejection reaction may be selected from the group consisting of rejection reactions of bone marrow transplant, heart transplant, cornea transplant, intestinal transplant, liver transplant, lung transplant, pancreas transplant, kidney transplant, and skin transplant, but is not limited thereto.

[0040] According to one embodiment of the present invention, the transplant rejection reaction may include graft-versus-host disease (GVHD).

[0041] According to one embodiment of the present invention, the microbiome strain is Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), Lactobacillus paracasei( Lactobacillus paracasei ), Lactobacillus gasseri( Lactobacillus gasseri ) and Lactobacillus acidophilus ( Lactobacillus acidophilus It may be selected from a group consisting of ).

[0042] In the present invention, the term "microbiome" refers to the entire genetic information of microorganisms inhabiting the human body or the microorganisms themselves. It is a compound word of "microbiota" (microorganisms inhabiting and coexisting with the human body) and "genome." It is known that the number of human microbiomes is more than twice the number of pure human cells and the number of genes is more than 100 times greater. Since the microbiome allows for the analysis of the principles of beneficial and harmful bacteria generation and the correlation between diseases, it refers to a field that can be widely utilized in research on the microbial environment within the human body, such as new drug development and the treatment of incurable diseases.

[0043] According to one embodiment of the present invention, the composition may increase the survival rate of the graft.

[0044] According to one embodiment of the present invention, the composition may regulate immune cells, and the immune cells may be cells selected from the group consisting of Th1, Th17, Treg, IL-10 producing B cell, plasma B cell, allo response T cell, Breg, B10, and CD19+IL-10+ cell.

[0045] According to one embodiment of the present invention, regulating the immune cells may involve suppressing the activity of Th1, Th17, plasma B cells, or allo-response T cells, increasing the expression of immune regulatory cells that have been reduced by treatment with an immunosuppressant, and increasing the activity of cells selected from the group consisting of Treg, IL-10 producing B cells, Breg, B10, and CD19+IL-10+ cells.

[0046] According to one embodiment of the present invention, the composition may protect against tissue damage, and the tissue may be a tissue selected from the group consisting of bone marrow, heart, cornea, intestine, liver, lung, pancreas, kidney, and skin.

[0047] According to one embodiment of the present invention, the composition may reduce the expression of IL-17.

[0048] According to one embodiment of the present invention, the composition may increase the expression of IL-10 or IFN-γ.

[0050] In addition, the present invention provides a pharmaceutical composition for post-transplant immunosuppression comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain as active ingredients.

[0052] The present invention will be explained in more detail below through examples. These examples are merely for the purpose of explaining the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples.

[0054] <Example 1> Preparation of Allogeneic Rejection Model and Confirmation of Allogeneic Reaction Suppression (in vitro)

[0055] To confirm the combined effect of the FK506 of the present invention and the microbiome on transplant rejection, an allogeneic cell model was used. Specifically, 2 × 10⁴ cells were placed in each well of a 96-well plate. 5 CD4+ T cells from normal recipients (Bclb / c, responder) and spleen cells from which T cells derived from irradiated recipients (allogeneic) or donors (C57BL / 6, stimulator, allogeneic) had been removed 2 × 10⁶ 5 Co-cultured with dogs. During co-culture, five types of Lactobacillus strains, including Lactobacillus acidophilus, were used in the homozygous model. Lactobacillus acidophilus , LA), Lactobacillus reuteri ( L. reuteri, LRe), Lactobacillus rhamnosus ( L. rhamnosus, LRh), Lactobacillus paracasei ( L. rhamnosus, LPC) or Lactobacillus casei ( L. casei,LC) was administered alone at doses of 1, 10, and 100 μg / ml, or in combination with FK506 0.3 mg / ml. As controls, syngenic and allogenic groups were used. Subsequently, to confirm the allore response in mice of each group, T cell proliferation responses (allore response) in cultured cells were verified using the 3H thymidine incorporation method.

[0057] As a result, as shown in Figure 1, T cell proliferation increased in the Allo group (positive control), while T cell proliferation was inhibited in the group administered FK506 alone. In addition, Lactobacillus rhamnosus or Lactobacillus paracasei were identified as microbiomes that exhibited a synergistic effect on the inhibition of T cell proliferation by FK506. In the group administered 100 μg / ml of each microbiome in combination with FK506, T cell proliferation was significantly inhibited compared to administration of FK506 alone, confirming that the combination of FK506 with Lactobacillus rhamnosus or Lactobacillus paracasei effectively inhibits the homeolytic reaction.

[0059] <Example 2> Confirmation of T cell activity regulation by combination of microbiome strain and FK506

[0060] It was confirmed whether the combined use of FK506 and the microbiome of the present invention regulates T cell activity. Specifically, mouse-derived spleen tissue was extracted, and T cells within the spleen tissue were stimulated with CD3 and then activated. At the time of CD3 stimulation, five strains of Lactobacillus and FK506 were treated alone or in combination in the same manner as in Example 1, and cultured for 3 days. After the culture was completed, the activity of Th1 and Th17, which are autoimmune pathogenic T cells, was analyzed by flow cytometry. In addition, the culture medium at the end of the culture was obtained, and the secretion of INF-γ and IL-17, inflammatory cytokines secreted by autoimmune pathogenic T cells in the culture medium, was measured by ELISA.

[0062] As a result, as shown in Fig. 2, compared to the control group, it was confirmed that Th1 and Th17 activity was significantly inhibited in the group treated with FK506 in combination with Lactobacillus acidophilus, Lactobacillus rhamnosus, or Lactobacillus paracasei. In addition, it was confirmed that the secretion of IFN-γ and IL-17 in the culture medium was significantly reduced in the group treated with FK506 in combination with Lactobacillus acidophilus or Lactobacillus paracasei (Fig. 3).

[0064] <Example 3> Confirmation of Simultaneous Regulation of T and B Cells by Combination of Microbiome Strain and FK506

[0065] We confirmed whether the combination of FK506 and the microbiome of the present invention simultaneously regulates T cells and B cells. Specifically, splenocytes were isolated from an animal model of graft-versus-host disease (aGVHD), and T cells and B cells were activated by treating them with CD3 (0.5 μg / ml) and LPS (100 ng / ml), which are activation conditions for T cells and B cells. Subsequently, Lactobacillus rhamnosus or Lactobacillus paracasei, which showed T cell regulatory effects in allogeneic reactions, were treated in combination with 0.3 nM FK506 at a concentration of 100 μg / ml and cultured for 24 hours. Afterward, the activity of immune cells, including Th1, Th17, Treg, IL-10 producing B cells, and plasma B cells (plasma cells), was analyzed by flow cytometry.

[0067] As a result, as shown in Figure 4A, compared to the control group, in the group treated with FK506 in combination with Lactobacillus acidophilus (LA) or Lactobacillus paracasei (LPC), the activity of Th1 and Th17, which are autoimmune pathogenic T cells, was significantly suppressed, and the activity of Treg, which are immune regulatory cells, was significantly increased, confirming the synergistic effect of FK506 and the microbiome on immune cell regulation. In addition, the activity of IL-10 producing B cells was significantly increased, and the activity of pathogenic plasma B cells was significantly decreased (Figure 4B), confirming the simultaneous regulatory effect of T cells and B cells.

[0069] <Example 4> Confirmation of Disease Activity Control in Acute Graft-Version-Host Disease Animal Model

[0070] We investigated whether the combination of FK506 of the present invention and Lactobacillus rhamnosus or Lactobacillus paracasei improves disease activity in acute graft-versus-host disease (aGVHD). Specifically, to construct an aGVHD model, recipient mice Balb / c (H-2k / d) were subjected to whole-body irradiation (TBI) of 690 cGy, and hematopoietic stem cells and splenocytes were isolated from the femur and tibia of donor mice C57BL / 6 (H-2k / b) to obtain 5 × 10 hematopoietic stem cells (BM, bone marrow). 6 and splenocytes 5 × 10 6 The cells were transplanted into recipient mice Balb / c (H-2k / d). Subsequently, after the onset of aGVHD, FK506 5 mg / kg and either Lactobacillus rhamnosus (LR) or Lactobacillus paracasei (LP) were administered orally once daily for 4 weeks at a concentration of 400 mg / kg each. Disease activity, body weight, and survival rate of mice in each group were measured once a week to confirm whether disease activity was suppressed (Fig. 5). As controls, the syngenic (syn) group transplanted with allogeneic cells; the Vehicle group, in which aGVHD was induced and physiological saline was injected; and groups administered FK506, Lactobacillus rhamnosus, and Lactobacillus paracasei, respectively, alone.

[0072] As a result, as shown in Figures 6 and 7, compared to the Syngenic group, disease activity significantly increased in the Vehicle group, body weight decreased due to aGVHD induction, and mouse survival decreased to 40% 5 days after aGVHD induction; however, in the groups administered with FK506 and Lactobacillus rhamnosus or Lactobacillus paracasei, disease activity significantly decreased and body weight increased compared to the Vehicle group. Furthermore, it was confirmed that disease activity was suppressed as the mouse survival rate remained at 100% until the end of the experiment. Additionally, in the groups administered FK506, Lactobacillus rhamnosus, or Lactobacillus paracasei alone, disease activity decreased and body weight increased compared to the Vehicle group; however, since the survival rate of each group at the end of the experiment was 60%, FK506 and Lactobacillus rhamnosus; Alternatively, it was confirmed that co-administration of Lactobacillus paracasei had an excellent effect in suppressing the disease activity of aGVHD.

[0074] <Example 5> Confirmation of tissue damage protection in an acute graft-versus-host disease animal model

[0075] It was confirmed whether the combined use of FK506 of the present invention and Lactobacillus rhamnosus or Lactobacillus paracasei protects against tissue damage in an aGVHD animal model. Specifically, mice from each group of Example 4 were humanely sacrificed at the end of the experiment, and liver and intestine tissues, which are target organs damaged in GVHD, were obtained. Tissue damage was confirmed by hematoxylin and eosin (H&E) staining and expressed as a histological score.

[0077] As a result, as shown in Figure 8, compared to the Syngenic group, the Vehicle group showed increased liver and tissue damage and increased histological indices, but the group administered FK506 and Lactobacillus rhamnosus; or Lactobacillus paracasei showed a significant decrease in histological indices, confirming that tissue damage was protected.

[0079] <Example 6> Confirmation of Immune Cell Regulation in an Acute Graft-Version-Host Disease Animal Model

[0080] It was confirmed whether the combination of FK506 of the present invention and Lactobacillus rhamnosus or Lactobacillus paracasei regulates immune cells in an aGVHD animal model. Specifically, spleen tissue was obtained from each group of mice sacrificed in Example 5 above, and the activity of immune cells, namely Th1, Th17, Treg, and CD8-INFγ cells, was analyzed by flow cytometry.

[0082] As a result, as shown in Figure 9, compared to the Syngenic group, Th1 and Th17 activity increased and Treg activity decreased in the Vehicle group, but in the group administered with FK506 and Lactobacillus rhamnosus or Lactobacillus paracasei, the increased Th1 and Th17 activity was significantly reduced and Treg activity was significantly increased.

[0084] <Example 7> Confirmation of Regulation of Allogeneic Response Cells and Inflammatory Factors

[0085] <7-1> Confirmation of Inhibition of Allogeneic T Cell Proliferation

[0086] It was confirmed whether the combined use of FK506 and the microbiome of the present invention inhibits the proliferation of allo-response T cells. Specifically, FK506 alone (1 nM) and FK506 (1 nM) with Lactobacillus gasseri ( L. gasseriThe proliferation of allogeneic T cells was confirmed for the combination of )(10 μg / ml); or Lactobacillus gasseri (10 μg / ml) and Lactobacillus acidophilus (10 μg / ml); or two types of microbiome (10 μg / ml each) and zinc (50 μM); or two types of microbiome (10 μg / ml each), zinc (50 μM), vitamin B9, and vitamin B12 (B9 + B12 20 μM); specifically, different human peripheral blood mononuclear cells (hPBMCs) were placed in a 96-well plate coated with anti-CD3 at a concentration of 0.5 μg / ml in a 1:1 ratio (1 × 10⁶ each). 5 In induced hPBMCs inoculated with Allo conditions (cell concentration), the above combination was applied and cultured for 72 hours. Subsequently, 10 μl of CCK8 was added to each well and incubated for 4 hours, after which the cell proliferation response was measured by absorbance at 450 nm. As a control, a Vehicle group in which the active ingredient was replaced with a solvent was used.

[0088] As a result, as shown in Figure 10, the proliferation of allogeneic T cells was inhibited in all treatment groups compared to the Vegicle group, and in particular, it was confirmed that the inhibitory effect on allogeneic T cells was excellent in the group administered with FK506, Lactobacillus gasseri, and Lactobacillus acidophilus; and in the group administered with microbiome, zinc, vitamin B9, and vitamin 12.

[0090] <7-2> Confirmation of Regulation of Inflammation-Related Factors Under Allogeneic Reaction Conditions

[0091] It was confirmed whether the combined use of FK506 and the microbiome of the present invention regulates the expression of inflammation-related factors under homologous response conditions. Specifically, the culture medium of each cell cultured in Example 7-1 was obtained, and the amounts of the inflammatory factor IL-17 and the inflammatory regulatory factor IL-10 in the culture medium were analyzed by ELISA.

[0093] As a result, as shown in Figure 11, it was confirmed that the amount of IL-17 was significantly reduced in all treatment groups compared to the Vehicle group. In addition, IL-10 was significantly reduced in the group treated with FK506 alone compared to the Vehicle group, indicating that treatment with an immunosuppressant reduced IL-10, but IL-10 expression was significantly increased in all treatment groups treated with FK506 and the microbiome.

[0095] <Example 8> Confirmation of Immunomodulatory Effects in hPBMCs Following T Cell Stimulation

[0096] <8-1> Confirmation of the Regulatory Effects of IL-17, IL-10, and IFN-γ Under T Cell Stimulation Conditions

[0097] We confirmed whether the combined use of FK506 and the microbiome of the present invention regulates IL-17 and IL-10 in human peripheral blood mononuclear cells (hPBMCs) under T cell stimulation conditions. Specifically, T cells were activated by treating PBMCs isolated from human peripheral blood with anti-CD3 at a concentration of 2 µg / ml. Subsequently, FK506 alone (1 nM) and FK506 (1 nM) with Lactobacillus gasseri ( L. gasseri )(10 μg / ml); or Lactobacillus gasseri (10 μg / ml) and Lactobacillus acidophilus (10 μg / ml); or two types of microbiome (10 μg / ml each) and zinc (50 μM); or a combination of two types of microbiome (10 μg / ml each), zinc (50 μM), vitamin B9 and vitamin B12 (B9 + B12 20 μM); were treated and cultured for 24 hours. After the culture was finished, the cell culture medium was obtained, and the amounts of IL-17, IL-10, and in the medium were measured by ELISA.

[0099] As a result, as shown in Figure 12, it was confirmed that the expression of IL-17 was significantly reduced in all treatment groups compared to the Vehicle group. In addition, IL-10 was not expressed in the FK506 alone treatment group, but the amount of FK506 increased in all groups administered FK506 in combination with the microbiome, and was significantly increased in the groups administered FK506 in combination with Lactobacillus gasseri and Lactobacillus acidophilus; microbiome and zinc; and microbiome, zinc, vitamin B9 and vitamin B12.

[0101] In addition, when the amount of IFN-γ was checked, compared to the Vehicle group, the amount of IFN-γ was significantly reduced in the FK506 alone group, but the amount of IFN-γ was significantly increased in all groups treated with FK506 and microbiome, and in particular, significantly increased IFN-γ was observed in the group administered with FK506 and Lactobacillus gasseri compared to other treatment groups (Fig. 13).

[0103] <8-2> Confirmation of Treg regulatory effects under T cell stimulation conditions

[0104] It was confirmed whether the combination of FK506 and the microbiome of the present invention regulates the expression of Treg reduced by treatment with an immunosuppressant. Specifically, cells from each group of Example 8-1 were obtained, and the expression of Treg was confirmed by flow cytometry.

[0106] As a result, as shown in Figure 14, compared to the Vehicle group, the expression of Treg was significantly reduced in the group treated with the immunosuppressant FK506 alone, but the reduced expression of Treg was significantly increased in all groups treated with FK506 and the microbiome in combination, and in particular, it was confirmed that the expression of Treg was significantly increased in the group treated with two types of microbiome and zinc; or two types of microbiome and zinc, vitamin B9, and vitamin B12 in combination.

[0108] <Example 9> Confirmation of Immune Cell Regulation Effects in hPBMCs Following LPS Stimulation

[0109] The combined use of FK506 and the microbiome of the present invention was used to confirm the immune cell regulatory effect in hPBMCs induced by LPS. Specifically, immune cells were activated in PBMCs isolated from human peripheral mononuclear cells by treating them with LPS at a concentration of 100 ng / ml. Subsequently, the cells were treated with FK506 alone; FK506 and Lactobacillus gasseri; Lactobacillus gasseri and Lactobacillus acidophilus; the microbiome and zinc; or the combination of the microbiome, zinc, vitamin B9, and vitamin B12, and cultured for 24 hours. After the culture was completed, cells from each group were obtained, and the expression of immune B cells, specifically Breg and B10 cells, as well as CD19-positive and IL-10-positive cells, was confirmed using flow cytometry.

[0111] As a result, as shown in Figure 15, compared to the Vehicle group, the expression of Breg was significantly reduced in the group treated with FK506 alone, but the expression of Breg was increased in all groups treated with the microbiome.

[0113] In addition, treatment with FK506 alone reduced B10 expression, and in all groups treated with microbiomes in combination with FK506, the reduced B10 expression was restored. In particular, in the group treated with two types of microbiomes in combination with zinc, vitamin B9, and vitamin 12, a significant increase in B10 cells was observed (Fig. 16). Furthermore, similar results were observed in CD19-positive and IL-10-positive cells, and CD19-positive and IL-10-positive cells significantly increased in the group treated with FK506 in combination with two types of microbiomes, zinc, vitamin B9, and vitamin 12 (Fig. 17).

[0115] Therefore, it was confirmed that the combined administration of FK506 and the microbiome of the present invention suppresses allogeneic reactions and regulates the activity of T cells and B cells in an allogeneic transplant cell model. Furthermore, it was confirmed that in an animal model of acute graft-versus-host disease, it reduces disease activity, increases survival rate, and protects against tissue damage. Additionally, it was confirmed that it can improve transplant rejection by reducing the activity of Th1 and Th17 cells and increasing the activity of Tregs. Moreover, it was confirmed that the combined administration of FK506 and the microbiome suppresses the proliferation of allogeneic T cells, inhibits the expression of IL-17, and increases the expression of IL-10, an immunomodulatory factor reduced by treatment with immunosuppressants. Furthermore, it was confirmed that in stimulated patient-derived PBMCs, it reduces IL-17, increases the expression of IL-10 and IFN-γ, and increases immunomodulatory cells.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of transplantation rejection or transplantation rejection disease comprising, as active ingredients a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain, wherein the microbiome strain is Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), Lactobacillus paracasei( Lactobacillus paracasei ), Lactobacillus gasseri( Lactobacillus gasseri ) and Lactobacillus acidophilus ( Lactobacillus acidophilus Composition selected from the group consisting of ): [Chemical Formula 1] Claim 2 A composition according to claim 1, wherein the transplant rejection reaction is a transplant rejection reaction selected from the group consisting of cells, blood, tissues, and organs. Claim 3 A composition according to claim 2, wherein the transplant rejection reaction is selected from the group consisting of rejection reactions of bone marrow transplant, heart transplant, corneal transplant, intestinal transplant, liver transplant, lung transplant, pancreas transplant, kidney transplant, and skin transplant. Claim 4 A composition according to claim 1, wherein the graft rejection reaction includes graft-versus-host disease (GVHD). Claim 5 delete Claim 6 In claim 1, the composition is one that increases the survival rate of the graft. Claim 7 In claim 1, the composition is one that regulates immune cells. Claim 8 A composition according to claim 7, wherein the immune cell is a cell selected from the group consisting of Th1, Th17, Treg, IL-10 producing B cell, plasma B cell, allo-response T cell, Breg, B10, and CD19+IL-10+ cell. Claim 9 A composition according to claim 7, wherein regulating the immune cells inhibits the activity of Th1, Th17, plasma B cells, or allo-response T cells. Claim 10 A composition according to claim 7, wherein regulating the immune cells increases the expression of immune regulatory cells that have been reduced by treatment with an immunosuppressant. Claim 11 A composition according to claim 7, wherein regulating the immune cells increases the activity of cells selected from the group consisting of Treg, IL-10 producing B cells, Breg, B10, and CD19+IL-10+ cells. Claim 12 A composition according to claim 1, wherein the composition protects against tissue damage. Claim 13 A composition according to claim 12, wherein the tissue is a tissue selected from the group consisting of bone marrow, heart, cornea, intestine, liver, lung, pancreas, kidney, and skin. Claim 14 A composition according to claim 1, wherein the composition reduces the expression of IL-17. Claim 15 A composition according to claim 1, wherein the composition increases the expression of IL-10 or IFN-γ. Claim 16 A pharmaceutical composition for post-transplant immunosuppression comprising, as an active ingredient, a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof and a microbiome strain, wherein the microbiome strain is Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), Lactobacillus paracasei( Lactobacillus paracasei ), Lactobacillus gasseri( Lactobacillus gasseri ) and Lactobacillus acidophilus ( Lactobacillus acidophilus Composition selected from the group consisting of ): [Chemical Formula 1]